Cargando…

Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report

Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and defi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pajno, Giovanni Battista, Bernardini, Roberto, Peroni, Diego, Arasi, Stefania, Martelli, Alberto, Landi, Massimo, Passalacqua, Giovanni, Muraro, Antonella, La Grutta, Stefania, Fiocchi, Alessandro, Indinnimeo, Luciana, Caffarelli, Carlo, Calamelli, Elisabetta, Comberiati, Pasquale, Duse, Marzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347813/
https://www.ncbi.nlm.nih.gov/pubmed/28257631
http://dx.doi.org/10.1186/s13052-016-0315-y
_version_ 1782514116438523904
author Pajno, Giovanni Battista
Bernardini, Roberto
Peroni, Diego
Arasi, Stefania
Martelli, Alberto
Landi, Massimo
Passalacqua, Giovanni
Muraro, Antonella
La Grutta, Stefania
Fiocchi, Alessandro
Indinnimeo, Luciana
Caffarelli, Carlo
Calamelli, Elisabetta
Comberiati, Pasquale
Duse, Marzia
author_facet Pajno, Giovanni Battista
Bernardini, Roberto
Peroni, Diego
Arasi, Stefania
Martelli, Alberto
Landi, Massimo
Passalacqua, Giovanni
Muraro, Antonella
La Grutta, Stefania
Fiocchi, Alessandro
Indinnimeo, Luciana
Caffarelli, Carlo
Calamelli, Elisabetta
Comberiati, Pasquale
Duse, Marzia
author_sort Pajno, Giovanni Battista
collection PubMed
description Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population. AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers’ preference and compliance. In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis. This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children.
format Online
Article
Text
id pubmed-5347813
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53478132017-03-14 Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report Pajno, Giovanni Battista Bernardini, Roberto Peroni, Diego Arasi, Stefania Martelli, Alberto Landi, Massimo Passalacqua, Giovanni Muraro, Antonella La Grutta, Stefania Fiocchi, Alessandro Indinnimeo, Luciana Caffarelli, Carlo Calamelli, Elisabetta Comberiati, Pasquale Duse, Marzia Ital J Pediatr Review Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population. AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers’ preference and compliance. In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis. This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children. BioMed Central 2017-01-23 /pmc/articles/PMC5347813/ /pubmed/28257631 http://dx.doi.org/10.1186/s13052-016-0315-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Pajno, Giovanni Battista
Bernardini, Roberto
Peroni, Diego
Arasi, Stefania
Martelli, Alberto
Landi, Massimo
Passalacqua, Giovanni
Muraro, Antonella
La Grutta, Stefania
Fiocchi, Alessandro
Indinnimeo, Luciana
Caffarelli, Carlo
Calamelli, Elisabetta
Comberiati, Pasquale
Duse, Marzia
Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title_full Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title_fullStr Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title_full_unstemmed Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title_short Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report
title_sort clinical practice recommendations for allergen-specific immunotherapy in children: the italian consensus report
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347813/
https://www.ncbi.nlm.nih.gov/pubmed/28257631
http://dx.doi.org/10.1186/s13052-016-0315-y
work_keys_str_mv AT pajnogiovannibattista clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT bernardiniroberto clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT peronidiego clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT arasistefania clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT martellialberto clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT landimassimo clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT passalacquagiovanni clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT muraroantonella clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT lagruttastefania clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT fiocchialessandro clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT indinnimeoluciana clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT caffarellicarlo clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT calamellielisabetta clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT comberiatipasquale clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT dusemarzia clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport
AT clinicalpracticerecommendationsforallergenspecificimmunotherapyinchildrentheitalianconsensusreport